Log In
Print
BCIQ
Print
Print this Print this
 

XMT-1107

  Manage Alerts
Collapse Summary General Information
Company Mersana Therapeutics Inc.
DescriptionFleximer-conjugated fumagillin analog
Molecular Target Methionine aminopeptidase 2 (MetAP2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

Partner

Teva Pharmaceutical Industries Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today